Ironwood Pharmaceuticals Issues FY26 Guidance, Shares Surge 57.7%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 02 2026
0mins
Should l Buy IRWD?
Source: Benzinga
- Sales Guidance Boost: Ironwood Pharmaceuticals anticipates 2026 US net sales for Linzess to reach between $1.125 billion and $1.175 billion, indicating strong market demand that is expected to drive future revenue growth.
- Revenue Expectations Rise: The company projects total revenue for 2026 to be between $450 million and $475 million, which is likely to enhance investor confidence and attract more capital inflow.
- Strong EBITDA Forecast: Ironwood expects adjusted EBITDA to exceed $300 million in 2026, indicating ongoing improvements in profitability that could elevate its market valuation.
- Significant Stock Surge: Following the announcement, Ironwood's shares surged 57.7% to $5.32, reflecting a positive market reaction to its growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRWD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRWD
Wall Street analysts forecast IRWD stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.170
Low
5.00
Averages
6.23
High
8.00
Current: 4.170
Low
5.00
Averages
6.23
High
8.00
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ironwood Pharmaceuticals Q1 2026 Earnings Call Insights
- LINZESS Sales Surge: Ironwood Pharmaceuticals reported Q1 2026 net sales of $272.5 million for LINZESS, reflecting a remarkable 97% year-over-year growth driven primarily by improved net pricing and a 5% increase in prescription demand, thereby reinforcing its market leadership.
- FDA Application Progress: Management announced that the FDA has accepted a supplemental New Drug Application for LINZESS in patients aged 2 to 5 years, with a priority review and a target action date set for May 24, 2026, which is expected to provide a new growth avenue for the company.
- Strong Financial Performance: The company reported total revenue of $106.5 million in Q1, with GAAP net income of $40.8 million and adjusted EBITDA of $76.7 million, indicating sustained profitability and cash flow, with expectations to exceed $300 million in adjusted EBITDA for 2026.
- Clear Future Outlook: Management reiterated its 2026 guidance, projecting LINZESS U.S. net sales between $1.125 billion and $1.175 billion and total Ironwood revenues between $450 million and $475 million, demonstrating confidence in stable growth and market conditions ahead.
See More
Ironwood Pharmaceuticals to Announce Q1 Earnings on May 7
- Earnings Announcement Schedule: Ironwood Pharmaceuticals is set to release its Q1 2023 earnings report on May 7 before market open, with consensus EPS estimate at $0.24 and revenue at $92.1 million, indicating investor interest in the company's financial performance.
- Historical Performance Review: Over the past two years, Ironwood has only beaten EPS estimates 13% of the time and revenue estimates 50% of the time, suggesting a relatively unstable performance in financial forecasting that may affect investor confidence.
- Expectation Adjustment Dynamics: In the last three months, EPS estimates have seen two upward revisions with no downward adjustments, potentially reflecting analysts' optimistic outlook on the company's future performance, despite the overall low probability of exceeding expectations.
- Market Reaction Analysis: Due to setbacks in the pipeline and an extended timeline for Apraglutide, market ratings for Ironwood have been downgraded, which may negatively impact the upcoming earnings report and influence stock price performance.
See More
Ironwood Pharmaceuticals to Present New Data at Digestive Disease Week
- Clinical Trial Data Presentation: Ironwood Pharmaceuticals will present long-term safety and tolerability data from the STARS clinical trial program at the 2026 Digestive Disease Week, focusing on adults with short bowel syndrome (SBS) dependent on parenteral support, aiming to enhance understanding of management and drive the development of new therapies.
- LANDMARK Survey Insights: The company will share findings from the LANDMARK survey involving 336 healthcare professionals, revealing significant treatment burdens faced by SBS patients on total parenteral nutrition, highlighting the urgent need for new therapies to improve patient quality of life and treatment outcomes.
- Linaclotide Research Advances: Ironwood will also showcase safety and efficacy results of linaclotide in pediatric patients aged 2-5 years with functional constipation, further solidifying its market leadership in constipation treatment and providing data support for future clinical applications.
- Market Potential Analysis: An estimated 18,000 adult patients in the U.S., Europe, and Japan suffer from SBS with parenteral support dependence, and Ironwood's apraglutide, as a next-generation GLP-2 analog, has the potential to significantly improve treatment outcomes for these patients, addressing substantial unmet medical needs.
See More
Ironwood (IRWD) Q4 2025 Earnings Call Transcript
See More
Ironwood Pharmaceuticals Q4 Earnings Miss Expectations
- Disappointing Earnings: Ironwood Pharmaceuticals reported a Q4 non-GAAP EPS of -$0.01, missing expectations by $0.02, indicating challenges in profitability that may affect investor confidence.
- Significant Revenue Decline: Q4 revenue of $47.71 million fell 47.3% year-over-year and missed the expected $52 million, reflecting weak market demand and increased competition, which could pressure future performance.
- 2026 Sales Guidance: The company projects U.S. LINZESS net sales between $1.125 billion and $1.175 billion in 2026, driven by improved net pricing and low-single digit demand growth, demonstrating long-term confidence in the product.
- Overall Revenue Outlook: Ironwood anticipates total revenue of $450 million to $475 million for 2026, exceeding the consensus of $410.5 million, indicating an optimistic view on future growth despite current underperformance.
See More
Ironwood Reports 2025 Financial Highlights and 2026 Guidance
- LINZESS Demand Growth: In 2025, LINZESS experienced an 11% year-over-year growth in EUTRx demand, further solidifying its position as the prescription market leader for IBS-C and CIC treatment, having treated over 5.7 million unique patients to date, indicating strong market demand and brand recognition.
- Strong Financial Performance: Ironwood reported total revenues of $296 million and GAAP net income of $24 million for 2025, with adjusted EBITDA of $138 million, demonstrating the company's ability to maintain profitability while effectively managing expenses, thereby strengthening its foundation for future investments.
- Positive 2026 Outlook: The company expects U.S. net sales of LINZESS to range between $1.125 billion and $1.175 billion in 2026, with adjusted EBITDA projected to exceed $300 million, reflecting confidence in LINZESS's continued growth and the advancement of the new drug apraglutide, aimed at enhancing shareholder value.
- Clinical Trial Progress: The confirmatory Phase 3 clinical trial design for apraglutide has been finalized, with site initiations expected to begin in the second quarter of 2026, which, if successful, could redefine the standard of care for patients with short bowel syndrome, showcasing Ironwood's strategic focus on innovative drug development.
See More
Ironwood Pharmaceuticals Q1 2026 Earnings Call Insights
- LINZESS Sales Surge: Ironwood Pharmaceuticals reported Q1 2026 net sales of $272.5 million for LINZESS, reflecting a remarkable 97% year-over-year growth driven primarily by improved net pricing and a 5% increase in prescription demand, thereby reinforcing its market leadership.
- FDA Application Progress: Management announced that the FDA has accepted a supplemental New Drug Application for LINZESS in patients aged 2 to 5 years, with a priority review and a target action date set for May 24, 2026, which is expected to provide a new growth avenue for the company.
- Strong Financial Performance: The company reported total revenue of $106.5 million in Q1, with GAAP net income of $40.8 million and adjusted EBITDA of $76.7 million, indicating sustained profitability and cash flow, with expectations to exceed $300 million in adjusted EBITDA for 2026.
- Clear Future Outlook: Management reiterated its 2026 guidance, projecting LINZESS U.S. net sales between $1.125 billion and $1.175 billion and total Ironwood revenues between $450 million and $475 million, demonstrating confidence in stable growth and market conditions ahead.
See More
Ironwood Pharmaceuticals to Announce Q1 Earnings on May 7
- Earnings Announcement Schedule: Ironwood Pharmaceuticals is set to release its Q1 2023 earnings report on May 7 before market open, with consensus EPS estimate at $0.24 and revenue at $92.1 million, indicating investor interest in the company's financial performance.
- Historical Performance Review: Over the past two years, Ironwood has only beaten EPS estimates 13% of the time and revenue estimates 50% of the time, suggesting a relatively unstable performance in financial forecasting that may affect investor confidence.
- Expectation Adjustment Dynamics: In the last three months, EPS estimates have seen two upward revisions with no downward adjustments, potentially reflecting analysts' optimistic outlook on the company's future performance, despite the overall low probability of exceeding expectations.
- Market Reaction Analysis: Due to setbacks in the pipeline and an extended timeline for Apraglutide, market ratings for Ironwood have been downgraded, which may negatively impact the upcoming earnings report and influence stock price performance.
See More
Ironwood Pharmaceuticals to Present New Data at Digestive Disease Week
- Clinical Trial Data Presentation: Ironwood Pharmaceuticals will present long-term safety and tolerability data from the STARS clinical trial program at the 2026 Digestive Disease Week, focusing on adults with short bowel syndrome (SBS) dependent on parenteral support, aiming to enhance understanding of management and drive the development of new therapies.
- LANDMARK Survey Insights: The company will share findings from the LANDMARK survey involving 336 healthcare professionals, revealing significant treatment burdens faced by SBS patients on total parenteral nutrition, highlighting the urgent need for new therapies to improve patient quality of life and treatment outcomes.
- Linaclotide Research Advances: Ironwood will also showcase safety and efficacy results of linaclotide in pediatric patients aged 2-5 years with functional constipation, further solidifying its market leadership in constipation treatment and providing data support for future clinical applications.
- Market Potential Analysis: An estimated 18,000 adult patients in the U.S., Europe, and Japan suffer from SBS with parenteral support dependence, and Ironwood's apraglutide, as a next-generation GLP-2 analog, has the potential to significantly improve treatment outcomes for these patients, addressing substantial unmet medical needs.
See More
Ironwood (IRWD) Q4 2025 Earnings Call Transcript
See More
Ironwood Pharmaceuticals Q4 Earnings Miss Expectations
- Disappointing Earnings: Ironwood Pharmaceuticals reported a Q4 non-GAAP EPS of -$0.01, missing expectations by $0.02, indicating challenges in profitability that may affect investor confidence.
- Significant Revenue Decline: Q4 revenue of $47.71 million fell 47.3% year-over-year and missed the expected $52 million, reflecting weak market demand and increased competition, which could pressure future performance.
- 2026 Sales Guidance: The company projects U.S. LINZESS net sales between $1.125 billion and $1.175 billion in 2026, driven by improved net pricing and low-single digit demand growth, demonstrating long-term confidence in the product.
- Overall Revenue Outlook: Ironwood anticipates total revenue of $450 million to $475 million for 2026, exceeding the consensus of $410.5 million, indicating an optimistic view on future growth despite current underperformance.
See More
Ironwood Reports 2025 Financial Highlights and 2026 Guidance
- LINZESS Demand Growth: In 2025, LINZESS experienced an 11% year-over-year growth in EUTRx demand, further solidifying its position as the prescription market leader for IBS-C and CIC treatment, having treated over 5.7 million unique patients to date, indicating strong market demand and brand recognition.
- Strong Financial Performance: Ironwood reported total revenues of $296 million and GAAP net income of $24 million for 2025, with adjusted EBITDA of $138 million, demonstrating the company's ability to maintain profitability while effectively managing expenses, thereby strengthening its foundation for future investments.
- Positive 2026 Outlook: The company expects U.S. net sales of LINZESS to range between $1.125 billion and $1.175 billion in 2026, with adjusted EBITDA projected to exceed $300 million, reflecting confidence in LINZESS's continued growth and the advancement of the new drug apraglutide, aimed at enhancing shareholder value.
- Clinical Trial Progress: The confirmatory Phase 3 clinical trial design for apraglutide has been finalized, with site initiations expected to begin in the second quarter of 2026, which, if successful, could redefine the standard of care for patients with short bowel syndrome, showcasing Ironwood's strategic focus on innovative drug development.
See More
